Holen Sie sich die Stockscreener-App
0.105
3.45%
0.0035
Vorhandelsmarkt:
.11
0.005
+4.76%
Schlusskurs vom Vortag:
$0.1015
Offen:
$0.1069
24-Stunden-Volumen:
10.91M
Relative Volume:
1.67
Marktkapitalisierung:
$14.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.61M
KGV:
-0.1167
EPS:
-0.9
Netto-Cashflow:
$-22.91M
1W Leistung:
-14.63%
1M Leistung:
-48.28%
6M Leistung:
-87.35%
1J Leistung:
-92.28%
1-Tages-Spanne:
$0.0956
$0.1079
1-Wochen-Bereich:
$0.0815
$0.135
52-Wochen-Spanne:
$0.0815
$1.44
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Firmenname
Bioline Rx Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
0.105 | 14.95M | 0 | -60.61M | -22.91M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2017-05-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-02-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-08-17 | Bestätigt | Maxim Group | Buy |
| 2015-07-27 | Bestätigt | ROTH Capital | Buy |
| 2015-06-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Bioline Rx Ltd Adr Aktie (BLRX) Neueste Nachrichten
BioLineRx announces strategic shift with licensing deals - Investing.com
BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks
BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks
BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com India
BioLineRx stock touches 52-week low at $0.14 amid downturn By Investing.com - Investing.com South Africa
BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks
BioLineRx stock plunges to 52-week low of $0.19 amid market challenges - Investing.com
BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks
BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com
BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com India
BioLineRx stock target cut, retains buy on Q3 financial results - Investing.com
BioLineRx Reports Strategic Moves in Q3 2024 - TipRanks
BioLineRx earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa
BioLineRx earnings beat by $0.04, revenue topped estimates - Investing.com India
Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com
Earnings call: BioLineRx announces Q3 results and strategic shifts By Investing.com - Investing.com South Africa
BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks
IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register
Options Volatility and Implied Earnings Moves Today, November 25, 2024 - TipRanks
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance
BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com
BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks
SEC Form 424B5 filed by BioLineRx Ltd. - Quantisnow
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Benzinga
BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks
BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks
BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India
BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks
BioLineRx secures US patent for cancer drug motixafortide - Investing.com
BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK
BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com
Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle
Market Insight: Bioline Rx Ltd ADR (BLRX)’s Notable Drop, Closing at 0.46 - The Dwinnex
BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com
BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks
Bioline Rx Ltd ADR (BLRX) Stock: A Year of Market Fluctuations - The InvestChronicle
Stock Market Recap: Bioline Rx Ltd ADR (BLRX) Concludes at 0.54, a -13.53 Surge/Decline - The Dwinnex
A new trading data show Bioline Rx Ltd ADR (BLRX) is showing positive returns. - SETE News
Metric Analysis: Bioline Rx Ltd ADR (BLRX)’s Key Ratios in the Limelight - The Dwinnex
BLRX overperforms with a 0.95 increase in share price - US Post News
Australia Single Molecule, Real-Time (SMRT) Sequencing Market Size & Outlook, 2030 - Grand View Research
BioLineRx Schedules Annual Shareholders Meeting - TipRanks
Financial Analysis: Bioline Rx Ltd ADR (BLRX)’s Ratios Unveil Key Insights - The Dwinnex
BLRX Stock: Exploring Bioline Rx Ltd ADR’s Growth - The InvestChronicle
Earnings call: BioLineRx beats Q2 goals with strong APHEXDA demand - Investing.com
BioLineRx’s Strong Quarter with APHEXDA Growth - TipRanks
Options Volatility and Implied Earnings Moves Today, August 15, 2024 - TipRanks
Finanzdaten der Bioline Rx Ltd Adr-Aktie (BLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):